Eppendorf awarded with ‘Customer Service of the Year’ and ‘Best New General Laboratory Product’ by SelectScience®.
The coveted 2017 Scientists’ Choice Awards, organized by SelectScience, were announced during the Pittcon 2017 Expo in Chicago, IL. The annual awards celebrate the laboratory products and manufacturers that make a difference to the industry. Scientists are invited to nominate, vote and review online.
Eppendorf was awarded ‘Customer Service of the Year.’ This award acknowledges the company which has received the highest average review rating for after-sales service across all products. “Scientists expect to read reviews and receive validation from others when investing in their laboratory, so it is a hugely significant accolade for Eppendorf that their customers see the company as best-in-class for service and support in the science industry,” said Kerry Parker, Editor-in-Chief for SelectScience.
The Eppendorf Centrifuge 5920 R received the award for ‘Best New General Laboratory Product.’ The centrifuge is the ideal product for high-throughput applications. “The new product was a result of a lot of engineering expertise. It’s especially important because we know what the voting process is here – this is voted on by scientists. It’s important for Eppendorf that we’re reaching our scientists and creating products that do make their processes better,” said Matthew Lieber, Product Manager at Eppendorf North America.
New microinjectors CellTram® 4 Air/Oil provide optimal sample control
Hamburg, February 2017
The new CellTram® 4 Air and CellTram® 4 Oil from leading life science company Eppendorf raise the bar in terms of ease of use and performance for manual microinjectors.
The CellTram® 4 Air is a pneumatic injector ideal for gentle holding of cells or embryos in suspension. At the same time it is highly suitable for the uptake and injection of cells (e.g., of sperm or ES cells). Therefore, users can set up their workstation with air injectors on both the holding and injection side and conduct microinjections entirely oil-free. Additional new features of the CellTram 4 Air are the dual coarse/fine drive, and the piston position scale, which allows setting the injector’s pressure characteristics according to personal preference.
The CellTram® 4 Oil is optimal for users who prefer the direct responsiveness of an oil-filled injector. It features a new oil-filling system that minimizes oil spills and helps save time during the filling process.
Both models have been designed with special emphasis on excellent ergonomics, ease of use and high precision. They also feature improved accessories, such as a scaled capillary holder 4 for reproducible mounting, and a new grip head 4 for easier capillary exchange and better user safety. For transgenic customers, a new capillary holder 4 (slim shape) is available that allows for injecting at angles <15° in combination with Eppendorf manipulators. Flat angle injections can help minimize mechanical trauma, thereby contributing to higher survival rates of the injected cells.
In Europe, the CellTram® 4m Air and Oil are registered as medical device (according to Medical Device Directive 93/42/EEC).
Dr. Rudolf Walczak, Global Product Manager Cell handling says: “Eppendorf has served as expert partners to embryologists and microinjectionists for more than 30 years. We are happy to offer our customers the new and highly improved CellTram 4 injectors. We are dedicated to helping them achieve the best possible results, both in research and in clinical applications.”
More information on Eppendorf’s CellTram 4 Air and Oil can be found at
International Stem Cell Community Day in Hamburg
Hamburg/Juelich, February 20, 2017 – On April 4, 2017 the first international Stem Cell Community Day will take place in Hamburg. Experts from academia and industry will discuss the status quo, perspectives, and challenges in stem cell cultivation for research and therapy, according to the event’s motto: “Bioprocessing Technologies in Stem Cell Research – Challenges and Chances for Commercialization”
Key note speakers are Steve Oh, PhD, from the Bioprocessing Technology Institute in Singapore, Dr. Stefan Braam, CEO of Pluriomics (Netherlands), and Todd McDevitt, PhD, principal investigator at the Gladstone Institutes (USA). Attendees can expect a comprehensive program including talks, a poster exhibition with final awarding, as well as hands on demonstrations of instruments and consumables for stem cell cultivation. Dr. Robert Zweigerdt from the Hannover Medical School (Germany) will be the scientific chairman.
The Stem Cell Community Day is organized by the leading life science company Eppendorf AG. “The commercial use of stem cell-based technologies requires reliable methods for the large-scale production of stem cells in consistent quality. We are very excited to bring together international experts and learn about the latest findings and trends in this exciting new field,” comments Dr. Karl Rix, Vice President Marketing, Portfolio & Support Bioprocess, Eppendorf.
The event will take place at the Hotel Crowne Plaza Hamburg – City Alster. The conference language is English. Registration is open until March 29, 2017. Poster abstracts can be submitted until March 10, 2017. For registration, the full program, and further information, please visit the event website www.stemcellday.de.
Media representatives are cordially invited.
For press accreditation please directly contact Dr. Ulrike Becken per phone +49 2461 980 475 or via email at email@example.com
Eppendorf Introduces the New BioFlo® 120 Bioprocess Control Station
Hamburg, January 30, 2017 – Leading life science company Eppendorf introduces the BioFlo 120, their latest bench scale fermentor/bioreactor system for research and development. This flexible instrument is capable of microbial fermentation as well as mammalian cell culture applications with a single platform. It features an extensive range of glass and BioBLU® Single-Use Vessel options (250 mL – 40 L). Universal connections for digital Mettler Toledo® ISM and analog sensors make it easy to monitor a variety of critical process parameters.
“We know that in research and development time is critical. Our priority was to develop a bioprocess system that is straightforward to set up and easy to use. By reducing the time required in learning to use new equipment, we free up scientists to spend more time on what is important, their research,” states Kevin Voll, product manager Eppendorf bioprocess.
The embedded software offers real-time local process control through an integrated touchscreen. The newly developed Auto Culture modes for push button control of microbial and cell culture applications drastically reduce the learning curve associated with new equipment. For additional process control capabilities and secure database management the BioFlo 120 can also be connected to Eppendorf SCADA platforms DASware® and BioCommand®.
“A very user-friendly system, which is self-explanatory” summarized Hamid Tehrani at RWTH Aachen University, after using the new control station for a few weeks. Ease of use and flexibility ensure the new bioreactor/fermentor serves the needs of scientists today and in the years to come – be it in academic, governmental, or industrial research settings.
The new BioFlo 120 bioprocess control station will be presented at the BioProcess International Europe in Amsterdam, the BioProcess International West in San Francisco, the BioPharm Asia in Singapore, and other industry events. Interested visitors can learn about the new product at the Eppendorf booths or at www.eppendorf.com/BioFlo120.
The new Eppendorf Storage Boxes
Hamburg, January 2017
The introduction of this new product line offers a complete systems solution for the storage of laboratory samples. Using this comprehensive modular concept, the nine different box formats may be combined to provide optimum solutions to individual storage requirements. The outside dimensions of the boxes are compatible with common freezer rack systems. In addition, the different inner grid variants offer the perfect fit for all common vessel formats:cryogenic tubes (1 mL - 5 mL), micro test tubes (0.5 mL - 5 mL), conical tubes (15 mL and 50 mL) and other laboratory vessels.
This space-saving approach, combined with the alphanumeric laser labeling of each individual sample position, will optimize sample storage and archiving in laboratories.
Please visit http://www.eppendorf.com/storageboxes for more information.
Eppendorf & Science Prize for Neurobiology 2017 - Call for Entries!
Hamburg, January 2017
Eppendorf and the journal Science are now accepting applications for the 2017 Eppendorf & Science Prize for Neurobiology. This annual international research prize of US$25,000 is awarded to young scientists for their outstanding contributions to neurobiological research based on methods of molecular and cell biology. Researchers who are not older than 35 years are invited to apply by June 15, 2017. The winner and finalists are selected by a committee of independent scientists, chaired by Science’s Senior Editor, Dr. Peter Stern.
The 2016 prize was won by the Israeli-American scientist Gilad Evrony, M.D., Ph.D. from Mount Sinai Hospital (New York, USA) for his work on developing technologies to sequence and analyze the genomes of single cells from the human brain. Gilad Evrony’s research has revealed a diversity of mutations in neuronal genomes indicating that every neuron in the brain carries a unique fingerprint of somatic mutations. Such mutations can cause focal brain malformations and may have a role in other unsolved neurologic diseases. The technology also allows, for the first time, reconstruction of develop-mental lineage trees in the human brain to study how cells proliferate and migrate to build the brain.
For more about the prize and film interview with Gilad Evrony, go to www.eppendorf.com/prize.
William Linton is new member of the Supervisory Board
Hamburg, Germany, January 13, 2017 – On January 9, 2017, William A. Linton was elected as a member of the Supervisory Board of Eppendorf AG, Hamburg, during an extraordinary Shareholders’ Meeting.
“With William Linton, we are very pleased to welcome a successful entrepreneur and experienced manager from the life science sector to our Supervisory Board,” stated Philipp von Loeper, Chairman of the Supervisory Board of Eppendorf AG.
William Linton founded Promega Corporation in 1978 and has served since then as its Chairman and Chief Executive Officer. Headquartered in Madison, Wisconsin, USA, Promega is a global life science research and diagnostics products company and employs over 1,400 people worldwide.
Israeli-American Scientist Wins 2016 Eppendorf & Science Prize
Hamburg, Germany, November 2016
The Israeli-American scientist Gilad Evrony, M.D., Ph.D. has won the 2016 Eppendorf & Science Prize for Neurobiology for his work on developing technologies to sequence and analyse the genomes of single cells from the human brain.
Dr. Evrony’s research, performed at Boston Children's Hospital and Harvard Medical School with Dr. Christopher Walsh and colleagues, has revealed a diversity of mutations in neuronal genomes indicating that every neuron in the brain carries a unique fingerprint of somatic mutations. Such mutations can cause focal brain malformations and may have a role in other unsolved neurologic diseases. The technology also allows, for the first time, reconstruction of developmental lineage trees in the human brain to study how cells proliferate and migrate to build the brain.
Gilad Evrony received his undergraduate degree from the Massachusetts Institute of Technology. He served in the Intelligence Division of the Israel Defense Forces and completed an M.D. and Ph.D. at Harvard Medical School, with graduate research in the laboratory of Dr. Christopher Walsh at Boston Children's Hospital. Dr. Evrony is currently pursuing clinical training in pediatrics at Mount Sinai Hospital in New York and continuing his research developing novel technologies for studying the brain and neuropsychiatric diseases.
The annual US$25,000 Eppendorf & Science Prize for Neurobiology honors scientists, like Dr. Evrony, for their ground-breaking research. Gilad Evrony is the 15th recipient of this international award which is awarded jointly by Eppendorf and the journal Science. Researchers who are not older than 35 years and have made outstanding contributions to neurobiological research based on methods of molecular and cell biology are invited to apply. The next deadline for applications is June 15, 2017. For more information about Dr. Evrony and the Prize, visit www.eppendorf.com/prize.
Eppendorf AG acquires Calibration Technology Ltd
Hamburg, Germany, November 3, 2016 – Hamburg-based Eppendorf AG have acquired Calibration Technology Ltd, headquartered in the National Technology Park Limerick, Ireland, on November 1. The company will continue to be managed as a wholly owned subsidiary of Eppendorf AG by its current Managing Director, Brian Kelly.
The acquisition of Calibration Technology Ltd will enable Eppendorf to expand its service presence into Ireland. “We have had a very good partnership with Calibration Technology for many years now, and are pleased that this acquisition will allow us to extend our service offering, especially for customers in regulated areas,” comments Thomas Bachmann, President & Chief Executive Officer of Eppendorf AG. Calibration Technology is accredited by the Irish National Accreditation Board (INAB) to ISO 17025 since 2007. The company has been an authorized Eppendorf Service Centre for the calibration and repair of pipettes and dispensers since 2008.
Changes in the Management Board of Eppendorf AG
Hamburg, Germany, October 31, 2016 – A partial rearranging of the responsibilities in the Management Board of Eppendorf AG will be taking effect in a move designed to further drive the successful implementation of the company's strategy. This includes the creation of a new Board position which will include Sales, Marketing and Service in order to focus on developing the market presence of Eppendorf.
As a result of these changes, the Supervisory Board of Eppendorf AG and Dr. Ralf Hermann, Board member, Chief Marketing & Portfolio Officer, have agreed that the Board mandate shall end by the end of October 2016. The Supervisory Board and the Management Board would like to thank Dr. Hermann for his many years of valuable and dedicated work and wish him all the best for the future.